



Press release from Emotra AB (publ)

Göteborg, August 21, 2020

## Emotra has signed a collaboration agreement for clinical studies with the General Psychiatry clinic at Örebro University hospital

**Emotra has lately been focusing on the indication area depression relapse. Our goal is to start a clinical study in 2020. Emotra's agreement with the General Psychiatry clinic (Allmänpsykiatriska kliniken) at Örebro University Hospital is another important step towards this goal. The aim is to document the connection between hyporeactivity and depression relapse.**

The collaboration agreement we have signed with the General Psychiatry clinic at Örebro University Hospital concerns the completion of a clinical study to determine the connection between hyporeactivity and depression relapse. In this agreement, the psychiatric clinic commits to carrying out clinical testing using Emotra's EDOR® method and to follow up the tested patients according to study protocols. As previously communicated in a press release on February 5, 2020, we have already signed a similar collaboration agreement with the University hospital of Warsaw for the same project.

On March 25, 2020, Emotra announced that we have also signed an agreement with Linköping University. That agreement mainly concerns planning, establishment of study protocols, as well as management and processing of study data. These tasks are crucial for assuring the Company's access to high-quality data that can be published. Professor Toomas Timpka, the attending physician at the Department of Health, Medicine and Caring Sciences (HMV), as well as the Division of Society and Health (SH), will manage the study efforts at Linköping University.

*"I am very pleased that we have signed yet another agreement that will help us carry out our clinical study. The fact that we have recruited another clinic in Sweden to participate in this study is very important, in my view. Since the prevalence of depression relapse is rather high, our assessment is that we will only need to recruit a few more clinics in order to gather the requisite amount of patient data. In this context, Emotra will act as the entity ordering the project, the supplier of the technology and test analyses, while the researchers will be in charge of the scientific process,"* says Daniel Poté, Emotra AB's CEO.

**For further information about Emotra, please contact:**

Daniel Poté, CEO, telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

*This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on August 21, 2020, under the above contact's supervision.*

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), AstraZeneca BioVentureHub, Pepparedsleden 1,  
SE-431 83 Mölndal, Sweden. Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)